Buy this digital health stock that's 'too compelling to ignore', says Raymond James

Raymond James upgraded Doximity to a strong buy from outperform and lowered its price target to $65 from $75—still implying roughly 40% upside from Thursday’s close—after what analyst Brian Peterson called a “significant dislocation” following fiscal Q2 results; he notes the stock trades at about 25x free cash flow and is “too compelling to ignore.” Peterson says Doximity has the “Moat, Margin, and Management” to justify a premium to vertical software peers, argues the recent pullback creates an attractive entry given durable growth drivers (workflow adoption, multi-product expansion and client portal benefits), and sees AI monetization as a further catalyst. Shares are down about 13% year-to-date.

Analysis

Raymond James upgraded Doximity to a strong buy from outperform while lowering its price target to $65 from $75, which still implies roughly 40% upside from Thursday’s close. Analyst Brian Peterson cited a "significant dislocation" after fiscal second-quarter results in May and highlights the stock trading at about 25 times free cash flow; shares are down roughly 13% year-to-date.

Peterson argues the company has the 'Moat, Margin, and Management' to justify a premium to vertical software peers and that the recent pullback creates an attractive entry given durable growth drivers. He points to historical outperformance of digital budgets at 2–3x, accelerating workflow adoption, multi-product expansion and client portal benefits as evidence of sustainable share gains, and identifies AI monetization as an incremental catalyst.

The combination of a lower target and an upgrade signals caution on near-term execution but conviction in longer-term optionality; valuation looks compelling only if adoption and AI monetization progress as argued. Key risks are persistent seasonality and failure to monetize AI or expand workflows; the investment case should be validated by upcoming operational metrics and management commentary.

Key Decisions for Investors

• Consider initiating or adding a position given the Raymond James upgrade and a $65 target implying ~40% upside, but treat valuation (25x FCF) as contingent on execution
• Size entries incrementally and avoid full allocation immediately to allow for confirmation after the fiscal Q2 dislocation and to observe whether seasonality moderates
• Monitor the specific KPIs Peterson cites—workflow adoption rates, multi-product expansion, client portal penetration and any early AI monetization revenue—and re-rate the thesis if these do not improve
• Use position risk controls (stop-losses or hedges) to limit downside if seasonality persists or AI monetization underperforms, and be prepared to trim exposure if guidance or analyst outlooks deteriorate